Back to Newsroom
Back to Newsroom

RDInvesting Provides Investors with Free In-Depth Equity Reports on AGCO, BEAT, GWAY and OVAS

Friday, 06 September 2013 09:00 AM

Topic:

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://www.rdinvesting.com/ and get exclusive access to our numerous stock reports and market updates.

AGCO Corporation (NYSE: AGCO) shares increased 0.86 percent to close at $57.26 a share Thursday. The stock traded between $56.40 and $57.63 on volume of 781,250 shares traded. Analysts at Morgan Stanley have recently initiated coverage on the company with an "overweight" rating. Shares of AGCO have gained approximately 16.5 percent year-to-date.

Find out more about AGCO including full access to the free equity report at:     
www.RDInvesting.com/AGCO

BioTelemetry Inc. (NASDAQ: BEAT) shares increased 3.22 percent to close at $8.98 a share Thursday. The stock traded between $8.65 and $9.32 on volume of 1.06 million shares traded. Analysts at Lake Street have recently initiated coverage on the company with a "buy" rating and a price target of $14.00. Shares of BioTelemetry have gained approximately 120.0 percent year-to-date.

Find out more about BioTelemetry including full access to the free equity report at:       
www.RDInvesting.com/BEAT

Greenway Medical Technologies, Inc. (NYSE: GWAY) shares spiked 5.62 percent to close at $15.03 a share Thursday. The stock traded between $14.42 and $15.51 on volume of 613,263 shares traded. Analysts at KeyBanc have recently initiated coverage on the company with a "buy" rating. Shares of Greenway Medical Technologies have fallen approximately 2.0 percent year-to-date.

Find out more about Greenway Medical Technologies including full access to the free equity report at:     
www.RDInvesting.com/GWAY

OvaScience Inc. (NASDAQ: OVAS) shares surged 11.58 percent to close at $13.39 a share Thursday. The stock traded between $12.40 and $14.01 on volume of 331,774 shares traded. Analysts at Wedbush have recently initiated coverage on the company with an "outperform" rating. Shares of OvaScience have gained approximately 14.0 percent year-to-date.

Find out more about OvaScience including full access to the free equity report at:    
www.RDInvesting.com/OVAS

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:  
Research Driven Investing    
[email protected]

Topic:
Back to newsroom
Back to Newsroom
Share by: